Taysha Gene Therapies (NASDAQ:TSHA) Research Coverage Started at BMO Capital Markets

BMO Capital Markets began coverage on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report released on Thursday, Marketbeat.com reports. The brokerage issued an outperform rating and a $5.00 price objective on the stock.

TSHA has been the topic of a number of other research reports. Needham & Company LLC reaffirmed a buy rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Monday, June 17th. Piper Sandler began coverage on Taysha Gene Therapies in a report on Tuesday, April 9th. They issued an overweight rating and a $9.00 target price on the stock. JMP Securities reaffirmed a market outperform rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Jefferies Financial Group reaffirmed a buy rating and issued a $8.00 target price (up previously from $2.00) on shares of Taysha Gene Therapies in a report on Tuesday, May 14th. Finally, Cantor Fitzgerald reaffirmed an overweight rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Ten analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of Buy and an average target price of $6.80.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA opened at $2.24 on Thursday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 3.38 and a current ratio of 3.38. The firm has a market cap of $418.92 million, a price-to-earnings ratio of -4.57 and a beta of 0.50. The business’s 50-day simple moving average is $2.97 and its 200-day simple moving average is $2.42. Taysha Gene Therapies has a 52 week low of $0.58 and a 52 week high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The business had revenue of $3.41 million for the quarter, compared to analyst estimates of $3.70 million. Taysha Gene Therapies had a negative return on equity of 782.81% and a negative net margin of 833.60%. During the same quarter in the prior year, the firm posted ($0.28) EPS. As a group, equities research analysts expect that Taysha Gene Therapies will post -0.43 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Taysha Gene Therapies

Hedge funds and other institutional investors have recently modified their holdings of the stock. Howard Capital Management Inc. bought a new position in shares of Taysha Gene Therapies during the 4th quarter worth approximately $25,000. Victory Capital Management Inc. bought a new position in shares of Taysha Gene Therapies during the 4th quarter worth approximately $28,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Taysha Gene Therapies during the 4th quarter worth approximately $31,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Taysha Gene Therapies during the 4th quarter worth approximately $38,000. Finally, Cannon Global Investment Management LLC bought a new position in shares of Taysha Gene Therapies during the 1st quarter worth approximately $69,000. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.